Researchers are exploring combinational techniques using PD-1/PD-L1 inhibitors to further enhance anti-tumor responses in both hematological malignancies and solid tumors in light of the encouraging outcomes from CAR T-cell treatments (147, 148). Here, CD274 is linked to neoplasm.